<DOC>
	<DOC>NCT02480465</DOC>
	<brief_summary>Efficacy and Safety of Lobeglitazone versus Sitagliptin in inadequately controlled by Metformin alone Type 2 Diabetes mellitus Patients with Metabolic syndrome.</brief_summary>
	<brief_title>Efficacy and Safety of Lobeglitazone Versus Sitagliptin</brief_title>
	<detailed_description>Efficacy and Safety of Lobeglitazone versus Sitagliptin in inadequately controlled by Metformin alone Type 2 Diabetes mellitus Patients with Metabolic syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>≥19 years old Waist line: male ≥ 90cm, female ≥ 85cm Applied to 1 or more categories listed below (NCEPATP III) 1. SBP ≥ 130mmHg and/or DBP ≥ 85mmHg and/or taking drug for BP control 2. HDLC: male &lt; 40mg/dl, female &lt; 50mg/dl and/or taking drug for HDLC increase 3. TG ≥ 150mg/dl and/or taking drug for TG control At visit 1: Applied to 1 or more categories listed below 1. Type 2 DM Patients who does not need stabilization period : 7% ≤ HbA1c ≤ 10%, if treated with Metformin ≥ 1000mg monotherapy at least 12 weeks prior to this study → Visit 3(Randomization) 2. Type 2 DM Patients who need stabilization period : 7% ≤ HbA1c ≤ 10%, if not treated with Metformin ≥ 1000mg monotherapy at least 12 weeks prior to this study (Applied to 1 or more categories listed below) ① Drug Naïve ② Taking Metformin &lt; 1000mg monotherapy and/or Taking Metformin &lt; 12 weeks prior to this study ③ Taking OHA At visit 2(After 12 weeks of stabilization period): 7% ≤ HbA1c ≤ 10% Patients who signed informed consent form Type 1 DM Patients or secondary DM Patients with ketoacidosis Patients with taking insulin &gt; 7 days within 12 weeks Hypersensitive to biguanide and/or glitazone and/or DPP4inhibitor Patients with taking corticosteroid &gt; 7 days within 4 weeks Patients with lactic acidosis Patients with galactose intolerance and/or Lapp lactase deficiency and/or glucosegalactose malabsorption Patients with innutrition and/or starvation and/or weakness and/or pituitary insufficiency and/or addisons disease History of malignant tumor within 5 years History of drug or alcohol abuse within 12 weeks Patients with congestive heart failure(NYHA class III~IV) or uncontrolled arrythmia within 6 months Patients with acute cardiovasvular disaese with 12 weeks Applied to 1 or more categories listed below 1. AST and/or ALT ≥ 3*ULN 2. Serum creatinine: male ≥ 1.5mg/dl, female ≥ 1.4mg/dl 3. Hb &lt; 10.5g/dl Women with pregnant, breastfeeding Childbearing age who don't use adequate contraception Patients who have participated in other clinical trials Not eligible to participate for the study at the discretion of investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>